上皮性卵巢癌中nm23蛋白和钙黏蛋白的表达及临床意义

目的:探讨nm23蛋白和钙黏蛋白在上皮性卵巢癌中的表达及临床意义。方法:采用免疫组化SP法检测30例良性上皮性卵巢肿瘤、20例交界性上皮性卵巢肿瘤和40例上皮性卵巢癌组织中nm-23和E-cad的表达。结果:在良性上皮性卵巢肿瘤、交界性上皮性卵巢肿瘤和上皮性卵巢癌组织中,nm-23的阳性表达率分别为16.6%、45.0%和72.5%,E-cad的阳性表达率分别为100.0%、85.0%和75.0%,组间差异有统计学意义(P<0.05)。卵巢癌组中,在不同的临床分期、有无淋巴结转移、术后残余病灶大小及术后生存年限各组间,nm-23和E-cad的阳性表达率差异均有统计学意义(P<0.05),且二者的表达强度呈显著正相关(P<0.05)。结论:nm-23和E-cad的表达率降低与上皮性卵巢癌的发生、发展有关,且二者有协同作用,二者的联合检测可作为上皮性卵巢癌评估病情、推测预后及指导治疗的重要参考指标。

Expression and clinical significance of nm-23 and E-cad in epithelial ovarian cancer

Objective:To study the expression and clinical significance of nm-23 and E-cad in epithelial ovarian cancer.Methods:SP immunohistochemical technique was used to detect the expression of nm-23 and E-cad in 30 cases of benign epithelial ovarian tumor,20 cases of borderline epithelial ovarian tumor and 40 cases of epithelial ovarian cancer.Results:The positive rates of nm-23 in benign epithelial ovarian tumor,borderline epithelial ovarian tumor and epithelial ovarian cancer tissue were 16.6%,45.0% and 72.5% respectively;the positive rates of E-cad were 100.0%,85.0% and 75.0%,respectively.The differences among the three groups were significant(P<0.05).In epithelial ovarian cancer groups,among the different clinical stage groups,the positive rates of nm-23 and E-cad were significantly different;between the two groups of lymph node metastasis or not,different size of residual focuses after operation groups and different survival time groups,the positive rates were also significantly different(P<0.05).And there was positive correlation between the expressions of nm-23 and E-cad(P<0.05).Conclusion:The abnormal expression of nm-23 and E-cad correlate with the occurrence and development of epithelial ovarian cancer,and there is synergism between the expressions of them.The combined detection of nm-23 and E-cad may be an important index to the diagnosis,evaluating prognosis and guiding clinical treatment of epithelial ovarian cancer.